SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TGEN - Targeted Genetics Corporation
TGEN 8.230+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: johnsto1 who wrote (279)3/26/2000 2:52:00 PM
From: johnsto1Read Replies (1) of 557
 
from bloomberg
Targeted Genetics Corp. rose 1 1/8, or 11 percent, to 13 5/8.
The company that researches gene therapy was rated ``buy' in new
coverage by Jay Kim at Chase H&Q.
``There are multiple players in gene therapy, and clearly I
think their position is one of the best.' Kim said. ``They've
done some really good work.'

Kim expects Targeted will have positive announcements in May
on a gene therapy treatment for head, neck and ovarian cancer. In
June, the company should have encouraging news about a treatment
for cystic fibrosis, Kim said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News